The market is primarily being driven by the rising use of biologics for the treatment of digestive disorders. There are numerous novel small molecules and cellular therapy-based new generation medications being researched right now. These contain tofacitinib and vedolizumab. Given the extensive frequency of digestive diseases, this arrival is expected to be substantial. Vedolizumab is being developed as a first-line biologic treatment for Crohn's disease. Entyvio, Humira, Amjevita, Cimzia, and Remicade have now received FDA approval in the United States for the treatment of Crohn's disease.